Daiichi scouts Europe for biotech, cardio deals

Daiichi Sankyo is seeking biotechnology acquisitions in Europe to advance cancer research, and will use $5 billion in funds to enter new markets and fill gaps in its heart-drug portfolio. Its acquisition last year of about 600 sales people in Germany, Turkey and Ireland from Merck Serono is an example of a type of deal that can help the Japanese company sell its products in markets in which it doesn't have a sales force, Daiichi's European operations chief said. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.